Form 4: Bristol-Myers Squibb Executive Samit Hirawat Reports Changes in Beneficial Ownership

Samit Hirawat, EVP, Chief Medical Officer, Drug Development at Bristol-Myers Squibb, reports transactions involving common stock and derivative securities, including vesting of market share units and distribution of performance shares.

Summary

• On March 10, 2025, Samit Hirawat, an executive at Bristol-Myers Squibb, reported changes in beneficial ownership of the company's securities.
• The transactions included the vesting of market share units granted on various dates (March 10, 2021, 2022, and 2023) and the distribution of performance shares earned under the 2022-2024 Long-Term Performance Award.
• These transactions resulted in the acquisition and disposal of common stock, as well as adjustments to the number of shares due to performance factors and tax withholdings.
• Following these transactions, Hirawat's direct ownership includes 79,263.486 shares of common stock.
• Hirawat also holds derivative securities, including market share units and performance shares, which convert into common stock based on performance metrics and vesting schedules.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing executive compensation. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The vesting of market share units and distribution of performance shares indicate that certain performance targets have been met, which could be viewed positively.

Future Outlook

The document outlines future vesting dates for market share units and performance shares, indicating continued equity-based compensation for the reporting person.

Industry Context

Executive compensation through equity-based awards is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a standard practice among large pharmaceutical companies like Johnson & Johnson, Pfizer, and Merck.
• These companies often use a mix of stock options, restricted stock units (RSUs), and performance-based shares to incentivize executives.
• The specific terms and conditions of these awards, such as vesting schedules and performance metrics, can vary widely based on company-specific goals and industry benchmarks.

Stakeholder Impact

• The vesting of equity awards can impact shareholder value through potential dilution.
• Executive compensation practices can influence employee morale and retention.

Key Dates